Jefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $17.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "BCRX is transitioning to a more capital efficient R&D model by prioritizing external innovation vs internal discovery, which we view as a (+)ve. Strong balance sheet, sustained double-digit% rev growth expectations, and tightly controlled expense growth underpins the strategic shift. We updated our model accounting for rev OpEX non-GAAP guidance. Also, navenibart ph.III completed enrollment w/ topline in 3Q27, and Netherton ph.I data remains on-track for YE26."